STOCKWATCH: Will Roche be the last to know?
This article was originally published in Scrip
In late 2000 when I was a fresh-faced investor just out of the anti-infectives group at SmithKline Beecham (SB), a colleague took me up to Manchester to see one of 3i's then private investments called NeuTec Pharma. During the meeting I had to point out that NeuTec's estimates for its lead product were 95% too high because they were mistakenly based on the largest instead of the smallest variant of the product that I had been managing at SB until a few months earlier. Imagine my surprise a few years later – after NeuTec's IPO and after 3i had divested its holding because NeuTec's products were all still un-partnered – when Novartis (which our fund owns) acquired NeuTec for $305m (scripintelligence.com, 09 June 2006).
You may also be interested in...
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.
Pharmaceutical shares are stronger than most as world stock markets dive downwards, but they are not immune to the coronavirus fallout. The effects will be felt by biopharma companies across many areas of their activity.